Astrazeneca (AZN) reported $15.5 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 4.1%. EPS of $1.06 for the same period compares to $2.10 a year ago.
The reported revenue represents a surprise of -1.74% over the Zacks Consensus Estimate of $15.78 billion. With the consensus EPS estimate being $2.18, the EPS surprise was -51.38%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Astrazeneca performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- BioPharmaceuticals- R&I- Fasenra- U.S.: $309 million compared to the $339.58 million average estimate based on three analysts. The reported number represents a change of +3.3% year over year.
- BioPharmaceuticals- R&I- Other- U.S.: $8 million compared to the $93.36 million average estimate based on three analysts. The reported number represents a change of -92% year over year.
- BioPharmaceuticals- R&I- Breztri- Europe: $55 million versus $53.5 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +31% change.
- BioPharmaceuticals- R&I- Breztri- U.S.: $153 million versus the three-analyst average estimate of $174.61 million. The reported number represents a year-over-year change of +2.7%.
- Alliance Revenue- Total: $959 million compared to the $916.42 million average estimate based on four analysts. The reported number represents a change of +34.3% year over year.
- Collaboration Revenue- Total: $6 million versus $173.65 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -99.3% change.
- BioPharmaceuticals- R&I- Fasenra- Emerging Markets: $36 million compared to the $30.13 million average estimate based on three analysts. The reported number represents a change of +56.5% year over year.
- BioPharmaceuticals- R&I- Breztri- Emerging Markets: $59 million versus the three-analyst average estimate of $81.3 million. The reported number represents a year-over-year change of +31.1%.
- BioPharmaceuticals- R&I- Tezspire- Emerging Markets: $16 million versus the three-analyst average estimate of $8.47 million. The reported number represents a year-over-year change of +300%.
- BioPharmaceuticals- R&I- Pulmicort- Emerging Markets: $134 million versus the three-analyst average estimate of $77.1 million. The reported number represents a year-over-year change of -5%.
- BioPharmaceuticals- R&I- Others- Emerging Markets: $38 million versus $41.83 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -5% change.
- BioPharmaceuticals- R&I- Emerging Markets: $468 million versus the three-analyst average estimate of $402.77 million. The reported number represents a year-over-year change of +14.7%.
View all Key Company Metrics for Astrazeneca here>>>
Shares of Astrazeneca have returned +0.4% over the past month versus the Zacks S&P 500 composite's no change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
